Jeanne M. Palmer, MD

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.

Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.

A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.

Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.

Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.

Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.

A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.

Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.

Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.

Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.

Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.

Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.

The panelists conclude their discussion by highlighting investigational agents to look forward to.

Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.

A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.

Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.

Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.

The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.

Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.

Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.

Experts discuss data on the recently approved agents fedratinib and pacritinib for myelofibrosis treatment.

A review of data on the use of the JAK inhibitor ruxolitinib for patients with myelofibrosis.

The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.

Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.

A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.

Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.

An overview of the treatment options for patients with polycythemia vera.

Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.

Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.

Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.